Herzuma and Truxima biosimilars to be distributed in Australia by Celltrion and to hospitals by Juno Pharmaceuticals.
Celltrion Healthcare (Celltrion) has entered into a partnership with Juno Pharmaceuticals (Juno) ( not to be confused with Juno Therapeutics) to market the trastuzumab biosimilar Herzuma and rituximab biosimilar Truxima in Australia. The company also launched Herzuma in Iraq. Under this co-marketing partnership, Celltrion Healthcare Australia the Marketing Authorization holder in Australia for Herzuma and Truxima will distribute the products in the market. Juno, a leading hospital supplier in Australia, will be responsible for sales promotion and providing hospital contracting services to Australian hospital customers.
Related news and insights
Fabhalta is a Factor B inhibitor that acts proximally in the alternative complement pathway of the immune system, providing comprehensive control of red blood cell (RBC) destruction within and outside the blood vessels (intra- and extravascular hemolysis [IVH and EVH])
Merck KGaA, a leading science and technology company, announced that its two Phase III EVOLUTION clinical trials (evolution RMS 1 and evolution RMS 2) investigating the efficacy and safety of evobrutinib did not meet their primary endpoints of reducing annualized relapse rates (ARR) in people with relapsing multiple sclerosis (RMS) compared to oral teriflunomide (Aubagio) (0.11 vs. 0.11 in evolution RMS 1 and 0.15 for evobrutinib vs. 0.14 for teriflunomide in evolution RMS 2, p=NS in both trials)